Literature DB >> 15159480

Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study.

E Cocco1, C Sardu, M Lai, G Spinicci, P Contu, M G Marrosu.   

Abstract

BACKGROUND: To assess the temporal trend in multiple sclerosis (MS) onset during the last 50 years in Sardinia, Italy.
METHODS: The authors used a cohort study to assess age at onset in 1,513 MS patients at the MS clinic in Cagliari, all born and living in Sardinia. They also assessed age at onset in 41 pairs of familial patients from two generations and 78 pairs of affected sibs. Each familial couple was paired with three couples of sporadic patients born in the same year as the familial ones. The time interval between the first symptoms and diagnosis was analyzed in first and second-diagnosed patients from both familial and control couples.
RESULTS: Mean age at onset progressively decreased from the most remote to the most recent decade of birth (log-rank test 778.27, p < 0.0001), being 41 years in the former decade and 22 years in the latter. A genetic influence was ruled out, because the younger member of familial patients coming from two generations had onset 14.0 years earlier than the older one (p < 0.0001), as in the paired control couples (11.6 years, p < 0.0001). Moreover, mean onset in younger sibs was 3.4 years earlier than in older ones (p = 0.01), similar to that of control couples (4.1 years, p < 0.0001).
CONCLUSION: Age at onset decreases progressively from older to younger generations in Sardinian MS patients. Nongenetic but recent widespread environmental changes might contribute to shortening of the preclinical phase-overt disease interval.

Entities:  

Mesh:

Year:  2004        PMID: 15159480     DOI: 10.1212/01.wnl.0000125194.27381.d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  The influence of parental age and gender on anticipation in familial B-cell malignancies.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Mitochondrial mutation in Iranian patients with multiple sclerosis, correlation between haplogroups H, A and clinical manifestations.

Authors:  Mojdeh Ghabaee; Motahar Omranisikaroudi; Shahla Amrisaroukolaei; Alipasha Meysamie; Mohammad Ali Sahraian; Asghar Bayati; Mohammad Hossein Sanati; Mossoud Houshman; Homa Sadeghian; Khalili Vajihazaman
Journal:  Cell Mol Neurobiol       Date:  2008-11-14       Impact factor: 5.046

3.  Multiple sclerosis in the province of Ferrara : evidence for an increasing trend.

Authors:  E Granieri; N-T Economou; R De Gennaro; M R Tola; L Caniatti; V Govoni; E Fainardi; I Casetta
Journal:  J Neurol       Date:  2007-11-16       Impact factor: 4.849

4.  Association between age at diagnosis of Graves' disease and variants in genes involved in immune response.

Authors:  Beata Jurecka-Lubieniecka; Rafal Ploski; Dorota Kula; Aleksandra Krol; Tomasz Bednarczuk; Zofia Kolosza; Andrzej Tukiendorf; Sylwia Szpak-Ulczok; Anita Stanjek-Cichoracka; Joanna Polanska; Barbara Jarzab
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

5.  TNFSF4 Gene Variations Are Related to Early-Onset Autoimmune Thyroid Diseases and Hypothyroidism of Hashimoto's Thyroiditis.

Authors:  Rong-Hua Song; Qiong Wang; Qiu-Ming Yao; Xiao-Qing Shao; Ling Li; Wen Wang; Xiao-Fei An; Qian Li; Jin-An Zhang
Journal:  Int J Mol Sci       Date:  2016-08-20       Impact factor: 5.923

6.  Age of onset in concordant twins and other relative pairs with multiple sclerosis.

Authors:  A Dessa Sadovnick; Irene M Yee; Colleen Guimond; Jacques Reis; David A Dyment; George C Ebers
Journal:  Am J Epidemiol       Date:  2009-06-22       Impact factor: 4.897

7.  Differences in Gene-Gene Interactions in Graves' Disease Patients Stratified by Age of Onset.

Authors:  Beata Jurecka-Lubieniecka; Tomasz Bednarczuk; Rafal Ploski; Jolanta Krajewska; Dorota Kula; Malgorzata Kowalska; Andrzej Tukiendorf; Zofia Kolosza; Barbara Jarzab
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.